Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 11/20 | 0.51 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28748189 | 0.99 | CXCR2 (0.50) | CXCR2CX3CR1CXCR1TSHRPTGES2 | |
| SCHEMBL27571764 | 0.89 | CXCR2 (0.43) | CXCR2CX3CR1CXCR1 | |
| SCHEMBL7552627 | 0.85 | TSHR (0.36) | CXCR2CX3CR1CXCR1TSHRKMT2A | |
| SCHEMBL27608152 | 0.85 | CXCR2 (0.51) | CXCR2CX3CR1CXCR1CA1 | |
| SCHEMBL7501094 | 0.83 | CXCR2 (0.44) | CXCR2CX3CR1TSHRKMT2A | |
| SCHEMBL27571719 | 0.83 | CXCR2 (0.43) | CXCR2CX3CR1SLC1A3SLC1A2 | |
| SCHEMBL7114363 | 0.83 | CXCR2 (0.36) | CXCR2CX3CR1CXCR1KMT2A | |
| SCHEMBL27574458 | 0.82 | CXCR2 (0.41) | CXCR2CX3CR1CXCR1PTGES2 | |
| SCHEMBL7110501 | 0.82 | CXCR2 (0.48) | CXCR2CX3CR1TSHR | |
| SCHEMBL7508715 | 0.82 | CXCR2 (0.44) | CXCR2CX3CR1CXCR1CA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110262386-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERPEUTICS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110256130-A1 | METHODS OF TREATING INFLAMMATORY DISORDERS | SQUARE 1 BANK | 2011-10-20 | — | — | US | disclosed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| CN-1334726-A | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2002-02-06 | — | — | CN | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256130-A1 | METHODS OF TREATING INFLAMMATORY DISORDERS | TNF, MPO, MMP8 | CXCR2 116/4885CX3CR1 6/4885CXCR1 540/4885 |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | CXCR2 1561/4885CX3CR1 199/4885CXCR1 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.